Oligonucleotides for use in allele-specific PCR

1. An oligonucleotide complementary to a target polynucleotide, wherein the oligonucleotide is selected from the group consisting of: SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17, or SEQ ID No: 18, wherein the nucleotide at the 3′ end of SEQ ID Nos. 9 and 10 is an LNA unit, the nucleotide one position away from the 3′ end of SEQ ID Nos. 11 and 12 is an LNA unit, the nucleotide two positions away from the 3′ end of SEQ ID Nos. 13 and 14 is an LNA unit, the nucleotide three positions away from the 3′ end of SEQ ID Nos. 15 and 16 is an LNA unit, and the nucleotide four positions away from the 3′ end of SEQ ID Nos. 17 and 18 is an LNA unit.

2. A method of detecting the presence or absence of a polymorphism in a target polynucleotide in a biological sample, comprising:

(a) providing an oligonucleotide primer complementary to a target polynucleotide, wherein the oligonucleotide primer comprises an LNA unit, a mismatch nucleobase, and an allele-specific nucleobase corresponding to an allele of the target polynucleotide, wherein the LNA unit is located at a position 0, −1, −2, −3, or −4 from the allele-specific nucleobase, the mismatch nucleobase is located at a position −1 from the allele-specific nucleobase, and the allele-specific nucleobase is located at the 3′-terminal position;

(b) combining the oligonucleotide primer of (a) and a polymerase enzyme with a biological sample suspected of containing a target polynucleotide under conditions amenable to hybridization of the oligonucleotide primer with the target polynucleotide and synthesis of a primer extension product; and

(c) detecting the presence or absence of a primer extension product, wherein the presence of a primer extension product is indicative of the presence of an allele corresponding to the allele-specific nucleobase.

3. The method of claim 2 , wherein the LNA unit is at the −2 position and the mismatch nucleobase is at the −1 position relative to the allele-specific nucleobase.

4. A method of quantitatively determining the frequency of a first allele and a second allele of a target polynucleotide in a biological sample, comprising:

(a) amplifying a target polynucleotide in a biological sample using a first oligonucleotide complementary to a first allele of the target polynucleotide, wherein the first oligonucleotide comprises an LNA unit, a mismatch nucleobase, and an allele-specific nucleobase corresponding to a first allele of the target polynucleotide;

(b) amplifying a target polynucleotide in a biological sample using a second oligonucleotide complementary to a second allele of the target polynucleotide, wherein the second oligonucleotide comprises an LNA unit, a mismatch nucleobase, and an allele-specific nucleobase corresponding to a second allele of the target polynucleotide;

(c) comparing the cycle threshold for the amplification of (a) and (b); and

(d) determining the frequency of the first allele and the second allele;

wherein the LNA unit is located at a position 0, −1, −2, −3, or −4 from the allele-specific nucleobase, the mismatch nucleobase is located at a position −1 from the allele-specific nucleobase, and the allele-specific nucleobase is located at the 3′-terminal position for the first and second oligonucleotides.

5. A method of quantitatively determining the frequency of an allele of a target polynucleotide in a biological sample, comprising:

(a) amplifying a target polynucleotide in a biological sample using a first oligonucleotide complementary to an allele of the target polynucleotide, wherein the first oligonucleotide comprises an LNA unit, a mismatch nucleobase, and an allele-specific nucleobase corresponding to a first allele of the target polynucleotide;

(b) calculating the cycle threshold for (a);

(c) comparing the cycle threshold for (a) with the cycle threshold for amplification of a known standard; and

(d) determining the frequency of the allele;

wherein the LNA unit is located at a position 0, −1, −2, −3, or −4 from the allele-specific nucleobase, the mismatch nucleobase is located at a position −1 from the allele-specific nucleobase, and the allele-specific nucleobase is located at the 3′-terminal position for the first oligonucleotide.

6. The method of claim 4 , wherein the LNA unit is at the −2 position and the mismatch nucleobase is at the −1 position relative to the allele-specific nucleobase.

7. The method of claim 5 , wherein the LNA unit is at the −2 position and the mismatch nucleobase is at the −1 position relative to the allele-specific nucleobase.

8. The oligonucleotide of claim 1 which is selected from SEQ ID NO: 9 and SEQ ID NO: 10, wherein the nucleotide at the 3′ end of SEQ ID Nos. 9 and 10 is an LNA unit.

9. The oligonucleotide of claim 1 which is SEQ ID NO: 9, wherein the nucleotide at the 3′ end of SEQ ID NO: 9 is an LNA unit.

10. The oligonucleotide of claim 1 which is SEQ ID NO: 10, wherein the nucleotide at the 3′ end of SEQ ID NO: 10 is an LNA unit.

11. The oligonucleotide of claim 1 which is selected from SEQ ID NO: 13 and SEQ ID NO: 14, wherein the nucleotide two positions away from the 3′ end of SEQ ID Nos. 13 and 14 is an LNA unit.

12. The oligonucleotide of claim 1 which is SEQ ID NO: 13, wherein the nucleotide two positions away from the 3′ end of SEQ ID NO: 13 is an LNA unit.

13. The oligonucleotide of claim 1 which is SEQ ID NO: 14, wherein the nucleotide two positions away from the 3′ end of SEQ ID NO: 14 is an LNA unit.

14. The oligonucleotide of claim 1 which is selected from SEQ ID NO: 11 and SEQ ID NO: 12, wherein the nucleotide one position away from the 3′ end of SEQ ID Nos. 11 and 12 is an LNA unit.

15. The oligonucleotide of claim 1 which is SEQ ID NO: 11, wherein the nucleotide one position away from the 3′ end of SEQ ID NO: 11 is an LNA unit.

16. The oligonucleotide of claim 1 which is SEQ ID NO: 12, wherein the nucleotide one position away from the 3′ end of SEQ ID NO: 12 is an LNA unit.

17. The oligonucleotide of claim 1 which is selected from SEQ ID NO: 17 and SEQ ID NO: 18, wherein the nucleotide four positions away from the 3′ end of SEQ ID Nos. 17 and 18 is an LNA unit.

18. The oligonucleotide of claim 1 which is SEQ ID NO: 17, wherein the nucleotide four positions away from the 3′ end of SEQ ID NO: 17 is an LNA unit.

19. The oligonucleotide of claim 1 which is SEQ ID NO: 18, wherein the nucleotide four positions away from the 3′ end of SEQ ID NO: 18 is an LNA unit.